| Literature DB >> 29051427 |
Joella Xu1, Guannan Huang2, Tai L Guo3.
Abstract
Bisphenol A (BPA), used in polycarbonate plastics and epoxy resins, has a widespread exposure to humans. BPA is of concern for developmental exposure resulting in immunomodulation and disease development due to its ability to cross the placental barrier and presence in breast milk. BPA can use various mechanisms to modulate the immune system and affect diseases, including agonistic and antagonistic effects on many receptors (e.g., estrogen receptors), epigenetic modifications, acting on cell signaling pathways and, likely, the gut microbiome. Immune cell populations and function from the innate and adaptive immune system are altered by developmental BPA exposure, including decreased T regulatory (Treg) cells and upregulated pro- and anti-inflammatory cytokines and chemokines. Developmental BPA exposure can also contribute to the development of type 2 diabetes mellitus, allergy, asthma and mammary cancer disease by altering immune function. Multiple sclerosis and type 1 diabetes mellitus may also be exacerbated by BPA, although more research is needed. Additionally, BPA analogs, such as bisphenol S (BPS), have been increasing in use, and currently, little is known about their immune effects. Therefore, more studies should be conducted to determine if developmental exposure BPA and its analogs modulate immune responses and lead to immune-related diseases.Entities:
Keywords: allergy; asthma; bisphenol A; bisphenol S; developmental; diabetes; epigenetics; immunotoxicity; mammary cancer; microbiome; multiple sclerosis
Year: 2016 PMID: 29051427 PMCID: PMC5606650 DOI: 10.3390/toxics4040023
Source DB: PubMed Journal: Toxics ISSN: 2305-6304
Summary of animal multiple sclerosis studies on BPA exposed offspring.
| Multiple Sclerosis Disease Models | Animal Model | Exposure Windows | BPA Dose | Routes of Administration | Diet | Effects | Reference |
|---|---|---|---|---|---|---|---|
| Autoimmune Encephalomyelitis (EAE) | Male and Female Mice (C57BL/6J and SJL/JCrHsd) | Gestation and Lactation | 10 μg/mL | 1% ethanol in drinking water | AIN-93G (casein-based phytoestrogen-free) | No Effect on EAE or INF-γ; decreased IL-17 in females | [ |
| Theiler’s Murine Encephalomyelitis Virus (TMEV) | Male and Female Mice (SJL) | Gestation and Lactation | 10 μg/kg BW | Charcoal-stripped corn oil via gavage | Not Specified | Earlier onset of disease; increased inflammation; decreased antibodies to virus | [ |
BPA: bisphenol A; BW: body weight.
Summary of animal diabetes (type 1 and type 2) studies on BPA exposed offspring.
| Diabetes Disease Model | Animal Model | Exposure Windows | BPA Dose | Routes of Administration | Diet | Effects | Reference |
|---|---|---|---|---|---|---|---|
| Female NOD/ShiLtJ Mice Offspring | Gestation and Lactation | 0.1, 1 or 10 mg/L | Deionized autoclaved drinking water | 2919X (minimal phytoestrogen content) | Increased insulitis, diabetes, Treg cells and apoptosis of β-cells, α-cells and macrophages in highest dose only | [ | |
| Female NOD/ShiLtJ Mice Offspring | From Gestation to End of Study | 1 mg/L | Deionized autoclaved drinking water | 2919X (minimal phytoestrogen content) | Increased insulitis, diabetes and apoptosis pancreatic cells macrophages; decreased phagocytic macrophages, IL-10, IL-4 and TNF-α | [ | |
| Male and Female Human Infants | 1st Trimester | ≤0.34 to >1.7 μg/L (measured, not dosed) | Measured exposure from environment, etc. | Not Specified | Lower adiponectins in male cord blood | [ | |
| Male Wistar Rat Offspring | Gestation and Lactation | 50 μg/kg | Gavage; dissolved in corn oil | Not Specified | Increased insulin and insulin resistance; reduced glycogen | [ | |
| Male and Female Wistar Rat Offspring | Gestation and Lactation | 50, 250 or 1250 μg/kg | Gavage; in corn oil | Standard or high-fat diet | Low dose only: increased body weight and insulin; altered β-cell function; high-fat diet and male had a greater effect | [ | |
| Male and Female OF-1 Mice Offspring | Prenatal (GD9-16) | 10 or 100 μg/kg | S.C. injection; in tocopherol-stripped corn oil | Soy/alfalfa-free | Low dose, males only: increased insulin, insulin sensitivity and glucose intolerance; altered β-cell function | [ | |
| Male and Female CD-1 Mice Offspring | Gestation and Lactation | About 0.25 μg/kg | In food | Phytoestrogen-free until weaning then LFD and half mice after 9 weeks old high-fat diet | No effect on glucose tolerance | [ | |
| Male OF-1 Mice Offspring | Prenatal (GD9-16) | 10 μg/kg | S.C. injection; in tocopherol-stripped corn oil | Soy/alfalfa-free | No effect for insulin sensitivity; glucose intolerance; increased NEFA | [ |
Treg cells: T regulatory cells; GD: gestation day; LFD: low butter-fat diet; S.C.: subcutaneous; NEFA: non-esterified fatty acids.
Figure 1Proposed mechanisms for increased type 2 diabetes risk following developmental bisphenol A (BPA) exposure.
Summary of allergy/asthma animal studies on BPA exposed offspring.
| OVA Sensitization | Animal Model/Sex | Exposure Windows | BPA Dose | Routes of Administration | Diet | Effects | Reference |
|---|---|---|---|---|---|---|---|
| Airway Sensitization | Male and Female C57BL/6 Offspring | GD6-PND21 | 0.5, 5, 50 or 500 μg/kg | Peanut oil via gavage | AIN76-semi-PD1RR chow (phytoestrogen-free) | Increased airway lymphocytes and lung inflammation in females; decreased airway neutrophils and lung inflammation in males; no effect on IgE, T cell subpopulations or BALF cytokines | [ |
| “Suboptimal” Peritoneal Sensitization | BALB/c offspring | Gestation and Lactation | 5 or 10 μg/mL | Drinking water | Phytoestrogen-free | Increased AHR, BALF eosinophils and IgE; no effect for IgG1 | [ |
| BALB/c offspring | Prenatal, perinatal or postnatal | 5 μg/mL | Drinking water | Phytoestrogen-free | Increased AHR and BALF eosinophils from prenatal and perinatal; no effect for postnatal only exposure | [ | |
| Peritoneal Sensitization | Female C57BL/6 Offspring | GD6-PND21 | 0.5, 5, 50 or 500 μg/kg | Peanut oil via gavage | AIN76-semi-PD1RR chow (phytoestrogen-free) | Decreased airway eosinophils and IgE; no effect on AHR | [ |
| Male and Female BALB/c Offspring | Gestation and Lactation | 50 ng, 50 μg or 50 mg/kg diet | In food | AIN-93G (phytoestrogen-free) | Increased IgE, IL-13 and INF-γ; decreased BALF leukocytes, eosinophils, IL-17 and CysLTs; decreased macrophages, PMN and lung inflammation in males; in females only: decreased BALF IL-4, IL-13 and TNF-α, increased lung RANTES and no effect on lung inflammation | [ | |
| BALB/cByJ Offspring | One week after mating period until birth or PND21 | 5 μg/mL | Drinking water | C1000 (phytoestrogen-free) | Prenatal: no effect on AHR or airway inflammation; perinatal: increased lung inflammation, IgE and IL-13 | [ | |
| Female Wistar rats offspring | GD15-PND21 | 0.5, 5 or 50 μg/kg | 4% ethanol in corn oil via oral | Rodent Diet 2018 (<20 pmol estrogen content) | Increased IgG, activated T cells, splenocyte proliferation, INF-γ, neutrophils and IL-10 (colon); no effect for IgE, Treg cells or IL-10 (spleen); decreased TGF-β (colon) | [ | |
| Gavage Sensitization | Male heterozygous offspring of OVA-TCR-Tg crossed with BALB/c | Gestation and Lactation | 0, 0.1 or 1 ppm BPA | In Food | Not Specified | Increased IL-13, INFγ, anti-OVA IgG1 and anti-OVA IgG2a; no change in IL-4; decreased OVA-specific T cells and Treg response to OVA | [ |
BPA: bisphenol A; OVA: ovalbumin; GD: gestation day; PND: postnatal day; BALF: bronchoalveolar lavage fluid; AHR: airway hyperresponsiveness; CysLT: cysteinyl leukotriene; PMN: polymorphonuclear neutrophil; Treg: T regulatory cells.
Summary of allergy/asthma epidemiological studies from BPA exposed infants/children.
| Sex/Age | Time of BPA Measurement | BPA Measured | BPA Levels Assessed From | Effects | Reference |
|---|---|---|---|---|---|
| Male and Female Infants | 1st Trimester | 0.8 μg/L | Median urine concentration | Non-monotonic increase of TSLP, IL-33 and IgE in cord blood | [ |
| Male and Female Children | 16 weeks gestation, 26 weeks gestation and birth | 2.4 μg BPA/g creatinine | Median urine concentration | Increased wheeze risk of 6 months old, but not 3 years | [ |
| Male and Female Children | 3rd trimester, 3, 5 and 7 years old | 1.8 ng/mL (3rd trimester), | Median urine concentration | Higher prenatal BPA levels inversely correlated with wheeze at 5 years and bronchodilator response; postnatal exposure increased wheeze, airway inflammation and aeroallergen sensitization at 7 years | [ |
| Male and Female Children | 12 and 32 weeks gestation | 2.4 μg BPA/g creatinine | Median urine concentration | Increased wheeze, respiratory tract infection and bronchitis risk from 6 months–7 years old; no change in atopy/IgE levels | [ |
| Male and Female Children | 16 weeks gestation, 26 weeks gestation and birth | 2.4 μg BPA/g creatinine | Median urine concentration | Decreased lung function at 4 years, but not 5 years; 16 week BPA only: increased wheeze and persistent wheeze risk | [ |
BPA: bisphenol A; TSLP: thymic stromal lymphopoietin.
Figure 2Allergy and asthma risks following developmental bisphenol A (BPA) exposure in female rodents. (A) Increased allergic airway and asthma risks result from developmental BPA and aeroallergen exposures; (B) increased airway hyperresponsiveness and allergy risks result from developmental BPA and early life antigen exposures; (C) lung inflammation may result from developmental BPA and late antigen exposures, but this is uncertain.
Figure 3Allergy and asthma risks following developmental bisphenol A (BPA) exposure in male rodents. (A) Decreased lung inflammation results from developmental BPA and aeroallergen exposures; (B) increased airway hyperresponsiveness and allergy risks result from developmental BPA and early life antigen exposures; (C) increased allergy risks result from developmental BPA and oral antigen exposures.
Figure 4Asthma risk increases following developmental bisphenol A (BPA) and aeroallergen exposures in humans.